Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Heel ultrasound can assess maintenance of bone mass in women with breast cancer.

Langmann GA, Vujevich KT, Medich D, Miller ME, Perera S, Greenspan SL.

J Clin Densitom. 2012 Jul-Sep;15(3):290-4. doi: 10.1016/j.jocd.2012.01.008. Epub 2012 Mar 16.

2.
3.

Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R.

Lancet Oncol. 2014 Dec;15(13):1460-8. doi: 10.1016/S1470-2045(14)71035-6. Epub 2014 Nov 11. Erratum in: Lancet Oncol. 2014 Dec;15(13):e587.

4.

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.

Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, Sereika SM, Vogel VG.

J Clin Oncol. 2008 Jun 1;26(16):2644-52. doi: 10.1200/JCO.2007.15.2967. Epub 2008 Apr 21.

5.

Quantitative ultrasound of the heel: correlation with densitometric measurements at different skeletal sites.

Faulkner KG, McClung MR, Coleman LJ, Kingston-Sandahl E.

Osteoporos Int. 1994 Jan;4(1):42-7.

PMID:
8148571
6.

Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.

Greenspan SL, Vujevich KT, Brufsky A, Lembersky BC, van Londen GJ, Jankowitz RC, Puhalla SL, Rastogi P, Perera S.

Osteoporos Int. 2015 Jun;26(6):1857-64. doi: 10.1007/s00198-015-3100-7. Epub 2015 Mar 20.

7.

Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population.

Haugeberg G, Ørstavik RE, Uhlig T, Falch JA, Halse JI, Kvien TK.

Osteoporos Int. 2003 Jun;14(4):312-9. Epub 2003 Apr 16.

PMID:
12730749
8.

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.

Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA.

J Clin Oncol. 2009 Mar 1;27(7):1047-53. doi: 10.1200/JCO.2008.19.1783. Epub 2008 Dec 15.

9.

Assessment of a new quantitative ultrasound calcaneus measurement: precision and discrimination of hip fractures in elderly women compared with dual X-ray absorptiometry.

He YQ, Fan B, Hans D, Li J, Wu CY, Njeh CF, Zhao S, Lu Y, Tsuda-Futami E, Fuerst T, Genant HK.

Osteoporos Int. 2000;11(4):354-60.

PMID:
10928226
10.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
11.

The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.

van Londen GJ, Perera S, Vujevich KT, Sereika SM, Bhattacharya R, Greenspan SL.

Bone. 2010 Mar;46(3):655-9. doi: 10.1016/j.bone.2009.10.019. Epub 2009 Oct 22.

12.
13.

Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study.

Miller KK, Meenaghan E, Lawson EA, Misra M, Gleysteen S, Schoenfeld D, Herzog D, Klibanski A.

J Clin Endocrinol Metab. 2011 Jul;96(7):2081-8. doi: 10.1210/jc.2011-0380. Epub 2011 Apr 27.

14.

[Bone mineral density in postmenopausal women with proximal femoral fractures--comparative study between quantitative ultrasonometry and gold standard DXA].

Schnabel M, Eser G, Ziller V, Mann D, Mann E, Hadji P.

Zentralbl Chir. 2005 Oct;130(5):469-75. German.

PMID:
16220445
15.

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.

Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A.

J Clin Oncol. 1997 Mar;15(3):955-62.

PMID:
9060533
17.

Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound?

Frost ML, Blake GM, Fogelman I.

Osteoporos Int. 2000;11(4):321-30.

PMID:
10928222
18.

Calcaneus ultrasonometry and dual-energy X-ray absorptiometry for the evaluation of vertebral fracture risk.

Frediani B, Acciai C, Falsetti P, Baldi F, Filippou G, Siagkri C, Spreafico A, Galeazzi M, Marcolongo R.

Calcif Tissue Int. 2006 Oct;79(4):223-9. Epub 2006 Sep 14.

PMID:
16969597
19.

Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.

Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D.

Climacteric. 2005 Sep;8(3):251-62.

PMID:
16390757
20.

Supplemental Content

Support Center